ROCK-ALS: Protocol for a Randomized, Placebo-Controlled, Double-Blind Phase IIa Trial of Safety, Tolerability and Efficacy of the Rho Kinase (ROCK) Inhibitor Fasudil in Amyotrophic Lateral Sclerosis

Objectives: Disease-modifying therapies for amyotrophic lateral sclerosis (ALS) are still not satisfactory. The Rho kinase (ROCK) inhibitor fasudil has demonstrated beneficial effects in cell culture and animal models of ALS. For many years, fasudil has been approved in Japan for the treatment of va...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Paul Lingor, Markus Weber, William Camu, Tim Friede, Reinhard Hilgers, Andreas Leha, Christoph Neuwirth, René Günther, Michael Benatar, Magdalena Kuzma-Kozakiewicz, Helen Bidner, Christiane Blankenstein, Roberto Frontini, Albert Ludolph, Jan C. Koch, The ROCK-ALS Investigators, Shahram Attarian, Mathias Bähr, Matthias Boentert, Nathalie Braun, Philippe Corcia, Isabell Cordts, Marcus Deschauer, Thorsten Grehl, Julian Grosskreutz, Andreas Hermann, Josua Kuttler, Teresa Lengenfeldt, Fabian Maass, Thomas Meyer, Susanne Petri, Yvonne Remane, Jens Schmidt, Joachim Schuster, Marie-Hélène Soriani, Jeffrey Statland, Jochen Weishaupt, Daniel Zeller, Eirini Zielke
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2019-03-01
coleção:	Frontiers in Neurology
Assuntos:	amyotrophic lateral sclerosis disease-modification clinical trial protocol ROCK inhibition study design
Acesso em linha:	https://www.frontiersin.org/article/10.3389/fneur.2019.00293/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!